Business · India Bureau
Dr Reddy's surges on Q2 results as analysts upgrade stance
Shares of Dr Reddy's Laboratories gained 4% following the release of second-quarter earnings, with multiple brokerages revising their investment recommendations upward.
LSN India ·
Dr Reddy's Laboratories stock climbed 4% in trading after the pharmaceutical company posted its Q2 results, triggering upgraded ratings from several research houses tracking the sector. Systematix Institutional Research elevated its position on the stock from 'Hold' to 'Buy', while Elara Securities upgraded its rating from 'Reduce' to 'Accumulate', signalling increased confidence in the company's near-term prospects. The dual upgrades reflect analyst assessments that the company's recent quarterly performance justifies a more constructive stance. The rating revisions come as domestic pharmaceutical stocks have attracted renewed investor interest, with several companies showing operational momentum and improved margins. Dr Reddy's, one of India's largest drugmakers with a significant presence in global markets, has been closely watched by institutional investors for signs of sustained performance improvement across its core business segments.